These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32349559)

  • 1. Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema.
    Shaw LT; Mackin A; Shah R; Jain S; Jain P; Nayak R; Hariprasad SM
    Expert Opin Investig Drugs; 2020 Jun; 29(6):547-554. PubMed ID: 32349559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-integrin therapy for retinovascular diseases.
    Bhatwadekar AD; Kansara V; Luo Q; Ciulla T
    Expert Opin Investig Drugs; 2020 Sep; 29(9):935-945. PubMed ID: 32657172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.
    Fong AH; Lai TY
    Clin Interv Aging; 2013; 8():467-83. PubMed ID: 23766636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
    Ünlü C; Erdogan G; Gunay BO; Kardes E; Akcay BI; Ergin A
    Int Ophthalmol; 2017 Feb; 37(1):147-158. PubMed ID: 27154721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of risuteganib and bevacizumab on AMD cybrid cells.
    Schneider K; Chwa M; Atilano SR; Shao Z; Park J; Karageozian H; Karageozian V; Kenney MC
    Exp Eye Res; 2021 Feb; 203():108287. PubMed ID: 33075294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial.
    Boyer DS; Gonzalez VH; Kunimoto DY; Maturi RK; Roe RH; Singer MA; Xavier S; Kornfield JA; Kuppermann BD; Quiroz-Mercado H; Aubel J; Karageozian HL; Park JY; Karageozian VH; Karageozian L; Sarayba MA; Kaiser PK
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):327-335. PubMed ID: 34185587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appointment Compliance in Patients With Diabetic Macular Edema and Exudative Macular Degeneration.
    Jansen ME; Krambeer CJ; Kermany DS; Waters JN; Tie W; Bahadorani S; Singer J; Comstock JM; Wannamaker KW; Singer MA;
    Ophthalmic Surg Lasers Imaging Retina; 2018 Mar; 49(3):186-190. PubMed ID: 29554386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration.
    Van Hove I; Hu TT; Beets K; Van Bergen T; Etienne I; Stitt AW; Vermassen E; Feyen JHM
    Prog Retin Eye Res; 2021 Nov; 85():100966. PubMed ID: 33775825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.
    Morjaria R; Chong NV
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1185-92. PubMed ID: 24856361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
    Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
    Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE.
    Weiss M; Sim DA; Herold T; Schumann RG; Liegl R; Kern C; Kreutzer T; Schiefelbein J; Rottmann M; Priglinger S; KortUEm KU
    Retina; 2018 Dec; 38(12):2293-2300. PubMed ID: 29068914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(13):1-22. PubMed ID: 23074517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
    Emerson MV; Lauer AK
    BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea.
    Nesmith BL; Ihnen M; Schaal S
    Retina; 2014 Dec; 34(12):2423-30. PubMed ID: 25062438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema.
    Wong CW; Wong TT
    Br J Ophthalmol; 2019 Oct; 103(10):1356-1360. PubMed ID: 31040133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection?
    Uyar E; Ulaş F; Alkan Y
    Curr Eye Res; 2021 Feb; 46(2):248-254. PubMed ID: 32635750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of the use of antioxidant and angioprotective agents in type 2 diabetes patients with diabetic retinopathy and age-related macular degeneration].
    Moshetova LK; Vorob'eva IV; Alekseev IB; Mikhaleva LG
    Vestn Oftalmol; 2015; 131(3):34-44. PubMed ID: 26310005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
    Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
    Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
    Kiss S; Malangone-Monaco E; Wilson K; Varker H; Stetsovsky D; Smith D; Garmo V
    J Manag Care Spec Pharm; 2020 Mar; 26(3):253-266. PubMed ID: 32020843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.